OSTX8:30 AMOS Therapies Achieves Statistically Significant Final Three-Year Overall Survival Benefit for Herlystic(TM)-Treated Patients in Phase 2b Pulmonary Metastatic Osteosarcoma TrialTrial Results • Phase 2Final 3-year overall survival results Tue, Oct 6, 2026, 8:30 AM EDTGostherapies.com
OSTX8:30 AMOS Therapies Appoints Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officerostherapies.com
OSTX8:22 AMOS Therapies Announces Brand Name 'Herlystic' Approved by World Health Organization for OST-HER2 (daznelimgene lisbac)ostherapies.com
OSTX6:30 AMOS Therapies Completes FDA Type C Statistical Methods Meeting and Provides Update on Global Regulatory Coordination for OST-HER2 Under Project Orbisostherapies.com
OSTX6:00 AMOS Therapies Achieves Incremental Alignment With FDA and Accepts Project Orbis Invitation From MHRA on OST-HER2 Metastatic Osteosarcoma Programostherapies.com
OSTX7:46 AMOS Therapies Announces Full Alignment with UK MHRA and EU EMA for Conditional Marketing Authorisation Application Filingostherapies.com
OSTX6:00 AMOS Therapies Achieves Statistically Significant Benefit for OST-HER2-Treated Patients in Interim 3-Year Overall Survival Analysis of Phase 2b Pulmonary Metastatic Osteosarcoma TrialInterim Data • Phase 2Interim data Tue, Sep 8, 2026, 6:00 AM EDTGostherapies.com
OSTX7:20 AMOS Therapies Provides OST-HER2 Metastatic Osteosarcoma Program Update and Announces Upcoming Conference Attendanceostherapies.com
OSTX7:40 AMOS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory UpdatesInterim Data • Phase 3Interim 3-year Overall Survival data Tue, Sep 1, 2026, 7:40 AM EDTGostherapies.com
OSTX8:45 AMOS Therapies Granted U.S. FDA Type C Statistical Methods Meeting to Review 2.5-Year Overall Survival Data for OST-HER2 in the Prevention or Delay of Recurrence in Fully Resected, Pulmonary Metastatic OsteosarcomaInterim Data • Phase 2Interim 3-year overall survival data Tue, Sep 1, 2026, 8:45 AM EDTGostherapies.com